BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
Summarize this article with:
Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(14min)CommentsSummaryBridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, aiming to surpass current market leaders.BBOT's lead candidate, BBO-8520, demonstrated a strong overall response rate in early Phase 1a data for KRAS G12C NSCLC, with no Grade 2+ adverse events.All three BBOT pipeline candidates are expected to report Phase 1 data in 2026, positioning the company for key clinical catalysts.The FDA granted Fast Track designation to BBO-8520, underscoring the potential for expedited development in KRAS G12C-mutated metastatic NSCLC. ferrantraite/E+ via Getty Images Investment Overview This is my first time initiating coverage of BridgeBio Oncology Therapeutics (BBOT), and the first time the company has been covered for Seeking Alpha. BBOT was initially formed as a subsidiary of BridgeBio (This article was written byEdmund Ingham14.44K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure:I/we have a beneficial long position in the shares of BMY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You